Optimizing ATR inhibition and Cisplatin Synergy in Ewing Sarcoma

EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ohmura, Shunya (VerfasserIn) , Grünewald, Thomas G. P. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 August 2024
In: Clinical cancer research
Year: 2024, Jahrgang: 30, Heft: 16, Pages: 3358-3360
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-24-1047
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-24-1047
Volltext
Verfasserangaben:Shunya Ohmura and Thomas G.P. Grünewald
Beschreibung
Zusammenfassung:EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy.
Beschreibung:Gesehen am 09.10.2024
Beschreibung:Online Resource
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-24-1047